Celyad Oncology S.A.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Georges Rawadi
- Full Time Employees
- 35
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Axis Business Park Mont-Saint-Guibert Belgium 1435
- IPO Date
- Jun 19, 2015
- CIK
- 0001637890
- Website
- celyad.com
- Similar Companies
- Business
- Celyad Oncology S.A. (Euronext: CYAD, Nasdaq: CYAD) is a clinical-stage biotechnology company focused on the discovery, development, and advancement of chimeric antigen receptor T-cell (CAR T) therapies for the treatment of cancer, including both hematological malignancies and solid tumors. Founded in 2007 and headquartered in Mont-Saint-Guibert, Belgium, with additional operations in New York, NY, the company develops allogeneic off-the-shelf and autologous personalized CAR T candidates targeting a broad range of cancer indications through proprietary technology platforms that address key limitations of current therapies, such as tumor targeting, persistence, and manufacturing scalability; its pipeline includes NKG2D-based programs such as CYAD-01, CYAD-02, and CYAD-101 in Phase 1 for various solid tumors and blood cancers, CYAD-221 (CD19-targeted) in preclinical for B-cell leukemia, universal CAR-T platforms, shRNA-mediated gene silencing technologies for next-generation allogeneic CAR T cells, and associated trademarks including C-CATH, C-CURE, DepleThink, Cycle1, CwalityCAR, and new engagers. The company operates primarily in the immuno-oncology segment, serving patients and healthcare providers globally with a lean structure of approximately 20-39 employees, supported by in-house GMP manufacturing capabilities and funding from sources like the Walloon Region of Belgium. In recent developments, Celyad Oncology announced a comprehensive strategic review in June 2025 encompassing potential asset sales, operational restructuring, mergers or business combinations, equity or debt financings, partnerships, and out-licensing of its CAR T and shRNA platforms, amid a cash position of €4.2 million as of December 31, 2024 sufficient only into Q3 2025; it completed a €1 million private placement with CFIP CLYD (UK) Limited in July 2025 extending runway to mid-Q4 2025, alongside significant cost reductions with R&D expenses dropping to €3.2 million in 2024 from €4.6 million in 2023 and G&A to €3.2 million from €6.0 million through project prioritization and headcount adjustments.
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
Celyad Oncology announces receipt of Nasdaq delisting notice
Celyad Oncology reports first quarter 2023 financial results and recent business highlights
Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq
Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price
Celyad Oncology announces receipt of Nasdaq notice
Celyad Oncology appoints Georges Rawadi as its new CEO
Celyad Oncology reports full year 2022 financial results and recent business highlights
Celyad Oncology to announce full year 2022 financial results and host conference call
Celyad Oncology announces non-cash impairment
Celyad Oncology Announces Non-Cash Impairment
REPEAT -- Celyad Oncology SA - Letter to Shareholders
Celyad Oncology SA - Letter to Shareholders
Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01
Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook
What Penny Stocks Trends Can Help You Profit in 2023?
Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property
Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights